Telix Pharmaceuticals (TLX) Assets (2023 - 2025)

Telix Pharmaceuticals (TLX) has disclosed Assets for 3 consecutive years, with $1.2 billion as the latest value for Q4 2025.

  • Quarterly Assets rose 17.38% to $1.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $991.7 million through Dec 2024, up 275.25% year-over-year, with the annual reading at $1.2 billion for FY2025, 17.38% up from the prior year.
  • Assets for Q4 2025 was $1.2 billion at Telix Pharmaceuticals, up from $991.7 million in the prior quarter.
  • The five-year high for Assets was $1.2 billion in Q4 2025, with the low at $264.3 million in Q4 2023.
  • Average Assets over 3 years is $806.6 million, with a median of $991.7 million recorded in 2024.
  • The sharpest move saw Assets soared 275.25% in 2024, then grew 17.38% in 2025.
  • Over 3 years, Assets stood at $264.3 million in 2023, then skyrocketed by 275.25% to $991.7 million in 2024, then grew by 17.38% to $1.2 billion in 2025.
  • According to Business Quant data, Assets over the past three periods came in at $1.2 billion, $991.7 million, and $264.3 million for Q4 2025, Q4 2024, and Q4 2023 respectively.